Persist-1: a phase III study of pacritinib (Pac) vs best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF)
Authors
Harrison, CSzoke, A
Suvorov, A
Egyed, M
Prasad, R
Mayer, J
Jakucs, J
Elinder, A
Recher, C
te Boekhorst, PA
Knapper, S
Somervaille, Tim C P
Ciceri, F
Quddus, F
Straetmans, N
Niederwieser, D
Dean, J P
Granston, T
Kiladjian, J J
Vannucchi, A
Nangalia, J
Mead, A
Mesa, R
Affiliation
Guy’s and St Thomas’ NHS Foundation Trust, LondonIssue Date
2015